Last reviewed · How we verify
NCT04309747
A Prospective, Multicenter Clinical Trial of Safety and Effectiveness of Nanosecond Knife Ablation for Liver Cancer
NA trial testing nanosecond knife liver cancer ablation in Liver Cancer in 190 participants. Status unknown.
1 April 2022
Quick facts
| Lead sponsor | First Affiliated Hospital of Zhejiang University |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 190 |
| Start date | 1 April 2020 |
| Primary completion | 1 April 2022 |
| Estimated completion | 1 December 2022 |
Drugs / interventions tested
- nanosecond knife liver cancer ablation
Conditions studied
- Liver Cancer — all drugs for Liver Cancer →
Sponsor
First Affiliated Hospital of Zhejiang University
Who can join
Eligibility, any sex, with Liver Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a prospective, multi-center, single-arm clinical trial. Four hospitals with national medical clinical trial institution qualifications are selected as clinical trial centers. Qualified participants will receive nanosecond pulse ablation therapy according to the routine procedures. The results will be recorded according to the requirements of the primary and secondary efficacy indicators. After then, statistical comparisons of effectiveness and safety of the product will be made according to groups.
Publications & conference data
6 peer-reviewed publications reference this trial (live from Europe PMC):
-
The Safety and Efficacy of Nanosecond Pulsed Electric Field in Patients With Hepatocellular Carcinoma: A Prospective Phase 1 Clinical Study Protocol.
Xu M, Xu D, Dong G, Ren Z, et al · · 2022 · cited 12× · PMID 35912221 · DOI 10.3389/fonc.2022.869316 -
Nanosecond pulsed electric field ablation-induced modulation of sphingolipid metabolism is associated with Ly6c2<sup>+</sup> mononuclear phagocyte differentiation in liver cancer.
Liu J, Fang C, Jin X, Tian G, et al · · 2023 · cited 8× · PMID 36587393 · DOI 10.1002/1878-0261.13372 -
Nano-Pulse Stimulation Therapy in Oncology.
Nuccitelli R, McDaniel A. · · 2024 · cited 5× · PMID 39119573 · DOI 10.1089/bioe.2024.0009 -
Threatment Strategies for Recurrent Hepatocellular Carcinoma Patients: Ablation and its Combination Patterns.
Zhao Y, Bai J, Wang X, Zhang Y, et al · · 2024 · cited 5× · PMID 38495485 · DOI 10.7150/jca.93885 -
Nanosecond pulsed electric field ablation as first-line curative therapy for hepatocellular carcinoma in high-risk locations a prospective multicenter.
Xu M, Zhang W, Xu D, Dong G, et al · · 2025 · cited 3× · PMID 40146263 · DOI 10.1097/js9.0000000000002361 -
Cardiovascular response to nanosecond pulses is milder in percutaneous ablation of hepatocellular carcinoma compared with microsecond pulses.
Kong HY, Jin QH, Chen XH, Xu DX, et al · · 2025 · PMID 38910059 · DOI 10.1016/j.hbpd.2024.06.004
Verify or expand the search:
- PubMed search for NCT04309747
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Liver Cancer
Currently open trials in the same condition.
- NCT07295275 — Safety and Efficacy of Transarterial ICG Fluorescence-Guided Laparoscopic Anatomical Liver Resection · recruiting
- NCT07410494 — Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
- NCT07295340 — Diagnostic Accuracy of Folate-Targeted NIR-II Carbon Dots for Ex Vivo HCC Detection · recruiting
- NCT07504367 — Large Language Models Assist in Tumor MDT · NA · recruiting
- NCT07447050 — Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial · Phase 2 · recruiting
Other First Affiliated Hospital of Zhejiang University trials
Trials by the same sponsor.
- NCT07537192 — Inulin-Spirulina Co-intervention for Insomnia Disorder · NA · not yet recruiting
- NCT07510867 — 18F-FAPI PET/CT and MRI in Gastric Cancer · not yet recruiting
- NCT07589647 — Research on the Efficacy and Safety of Targeted Suprachiasmatic Nucleus Electrical Stimulation for Improving Metabolic D · NA · recruiting
- NCT07525765 — AI-assisted Decision-making of Reoperation for Postoperative Bleeding of Gastric Cancer · recruiting
- NCT07468162 — Characteristic Electroencephalogram of General Anesthesia · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04309747 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by First Affiliated Hospital of Zhejiang University
- Last refreshed: 17 March 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04309747.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing